CEBPA and intrahepatic cholangiocarcinoma: For the WHO, it is necessary at least 20% blasts for the diagnosis because “There is insufficient data to support any change in the blast cutoff criterion for AML with CEBPA mutation.” Conversely, the ICC assumes that 10% or more blasts are sufficient for the diagnosis.